Inflammatory cardiomyopathy: Still many questions await answers  by Paleček, Tomáš
Available online at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/crvasa
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 4 1 – e 3 4 4☆The study was s
Regional Developm
1.1.00/02.0123).Editorial — Special issue: Heart FailureInflammatory cardiomyopathy: Still many questions
await answers$Heart failure represents a major public health problem as it
belongs to themost signiﬁcant causes of morbidity andmortality
in developed countries. Dilated cardiomyopathy (DCM) is a
common cause of heart failure. DCM is deﬁned by the presence
of left ventricular (LV) dilatation and LV systolic dysfunction in
the absence of abnormal loading conditions (hypertension, valve
disease) or coronary artery disease sufﬁcient to cause global
systolic impairment [1]. The long-term prognosis of the disease
has improved remarkably during the past 20 years [2]. However,
despite progress in drug treatment and non-pharmacological
therapeutic options like cardiac resynchronization therapy, DCM
still remains the most frequent reason for heart transplantation
in adults and children [3].
DCM is not a single disease but a heterogeneous group of
disorders comprising familial and acquired forms. Familial
forms of DCM represent about 20% of cases and 440 genes
have been implicated in causing disease [4]. Today, myocarditis
is thought to be one of the major causes of acquired DCM [5].
The etiologies of myocarditis are manifold and include viral,
bacterial, rickettsial, helminthic, fungal, and protozoal infec-
tions as well as non-infectious causes like autoimmune, toxic,
and allergic forms. Viral infection is regarded as the most
common cause of acute myocarditis. The pathophysiology of
myocarditis is still not completely understood. Based on data
from murine models of enteroviral myocarditis, the course of
viral myocarditis may be divided into 3 phases [6]. The early
phase of myocarditis is initiated by infection of cardiac myo-
cytes, ﬁbroblasts or endothelial cells through receptor-mediated
endocytosis. At this moment, myocyte injury may result from
either direct virus-mediated lytic processes or emerging anti-
viral immune response. Thus acute phase of myocarditis takes
only a few days. The second, subacute phase covers several
weeks to months and is characterized by (auto)immune reac-
tions arising from activation of virus-speciﬁc T-lymphocytes
together with antibody and cytokine (tumor necrosis factor α,
interleukins 1 and 6) production. All these processes aim to
enhance viral clearance, but they may aggravate cardiac
damage and contractile dysfunction. In many patients, immune
responses declines with successful virus elimination and
LV function recovers. However, in some individuals chronicupported by PRVOUK-P35/LF1/5 and European
ent Fund—Project FNUSA-ICRC (No. CZ.1.05/immune stimulation and autoimmune processes may persist
due to incompletely cleared virus infection or in response to the
virus- and immune-mediated tissue damage. Both these cellu-
lar and humeral inﬂammatory processes contribute to the
progression of chronic myocardial injury and represent a third
phase characterized by ventricular remodeling and develop-
ment of DCM.
The increasing knowledge about the pathogenic link between
myocardial inﬂammation and injury lead to the deﬁnition of a
new and distinct entity, inﬂammatory cardiomyopathy (ICM) in
the 1996 WHO classiﬁcation of cardiomyopathies. ICM was
deﬁned as inﬂamed myocardium assessed histologically (e.g.,
myocarditis) in association with cardiac dysfunction [7]. The
histopathological criteria at that time were the Dallas criteria,
which distinguished active, recurrent, healing, and borderline
myocarditis [8]. According to the Dallas criteria, acute myocardi-
tis was deﬁned by lymphocytic inﬁltrates in association with
myocyte necrosis. Borderlinemyocarditis was then characterized
by inﬂammatory inﬁltrates without evidence of myocyte necro-
sis. However, the assessment of myocardial inﬂammation by
Dallas criteria is limited by several factors including low sensi-
tivity, high interobserver variability and sampling error [9].
Importantly, the isolated histopathological evaluation also does
not say anything about persistent myocardial infection. The nice
example of the limitation of the Dallas criteria represents the
Myocarditis Treatment Trial, which failed to show a beneﬁt of
immunosuppressive therapy of ICM [10]. The negative results of
this trial might have been inﬂuenced by a lack of consensus in
histopathological interpretation of endomyocardial biopsy (EMB)
ﬁndings and, maybe more importantly, by the absence of
molecular biological analyses of EMB in order to detect persistent
(viral) infection. Thereby, patients with viral infectionmight have
been treated with immunosuppressive agents, which could have
increased virus replication and damaged the myocardium.
Therefore, more objective and comprehensive immunohis-
tological and microbiological evaluation of myocardial speci-
mens was introduced and gained acceptance [9]. Immuno-
histochemistry allows the quantitative characterization and
localization of mononuclear inﬁltrating cells. Indeed, with the
use of immunohistological methods, the number of EMB
revealing myocarditis markedly increased [11]. In a cohort of
299 patients with DCM, who underwent EMB, Kühl et al. found
positive Dallas criteria for active or borderline myocarditis
in 5.6%; however, immunohistological markers of myocardial
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Health Federation consensus meeting from 1999, EMB is cur-
rently considered to be inﬂamed by immunohistochemical
detection of focal or diffuse mononuclear inﬁltrates (T lympho-
cytes and macrophages) with 414 cells/mm2 [13]. These inﬁl-
trating cells could include T- and B-lymphocytes, their activated
forms, and up to 4 monocytes or macrophages/mm2. At the
same time, a causative microbial agent had to be identiﬁed or
excluded by molecular biological methods covering polymerase
chain reaction (PCR) or in situ hybridization [14]. Based on the
results of such comprehensively evaluated EMB, several sub-
types of DCM may be distinguished: (1) dilated cardiomyopathy
with negative EMB (presumably due to the healed inﬂammation
and virus elimination or due to other non-infectious causes), (2)
ICM or autoreactive ICM, which is characterized by persistent
inﬂammation as demonstrated by immunohistochemistry and
no detectable infectious agent, and (3) chronic viral heart
disease or viral ICM deﬁned by the presence of chronic viral
infection that may be (or not) accompanied by myocardial
inﬂammation [15]. Therefore, despite the progress in noninva-
sive diagnostics of myocarditis, mainly in the ﬁeld of magnetic
resonance imaging, EMB still represents a gold standard in the
diagnosis of various types ICM as it is the most sensitive
method for detection of myocardial inﬂammation and the only
tool to demonstrate the presence or absence of persistent
myocardial infection, mostly of viral origin. Importantly, only
such complex EMB evaluation allows tailoring the therapy of
DCM in more detail [16]. The patients with ICM and negative
PCR for infectious agent may beneﬁt from combined immuno-
suppressive therapy as was shown in TIMIC trial [17]. If Borrelia
burgdorferi or other non-viral infectious agent is found in EMB,
antibiotic treatment may lead to improvement in LV size and
function [18]. The most difﬁcult situation represents viral ICM.
Antivirotics would be effective in the very early stages of
myocarditis, but, unfortunately, most adult patients present in
the chronic phases of disease. Immunomodulatory therapy
using interferon beta has been tested for treatment of chronic
viral cardiomyopathy [19]; however, results of randomized,
placebo-controlled trials are lacking.
In recent years, the prognostic value of complex evaluation of
EMB specimens also gained attention. In the study by Caforio
et al., 174 patients with immunohistologicaly deﬁned myocardi-
tis were followed for 24 months [20]. A presence of viral genome
in EMB was shown to be a signiﬁcant predictor of adverse
prognosis with respect to survival free from heart transplanta-
tion or death. Similarly, Kühl et al. demonstrated that viral
persistence in the myocardium is associated with progressive
cardiac dysfunction, whereas the clearance of viral genomes in
control EMB at 7 months follow-up was accompanied by
signiﬁcant improvement in LV ejection fraction [21]. The impor-
tance of viral genome persistence, speciﬁcally enteroviral RNA,
for adverse clinical outcome of patients with DCM was demon-
strated also by Why et al. [22]. Immunohistological evidence
of myocardial inﬂammation (with or without evidence of viral
genome) was demonstrated to predict cardiovascular death and
the need for heart transplantation in the study of Kindermann
et al., in which 181 consecutive patients with clinically suspected
viral myocarditis were followed up for a mean of 59 months [23].
Interestingly, neither the histopathological criteria nor the detec-
tion of viral genome was a predictor of poor outcome.In this issue of the journal, Krejčí et al. present very interest-
ing results of a prospective study focused on the evolution of
echocardiographic parameters and clinical status of patients
with recently diagnosed symptomatic DCM [24]. Seventy patients
with recently occurred DCM with LV ejection fractiono40% and
the history of heart failure symptoms less than 12 months
underwent comprehensively evaluated EMB. In agreement with
previous studies, immunohistochemically deﬁned myocardial
inﬂammation was found in half of the study population and
viral genome was detected in 61% of patients with parvovirus
B19 being far the most common agent. All patients were treated
only by standard heart failure medication according to current
recommendations; it means, none of the subjects was treated by
immunosuppression or immunomodulatory approaches. At 6
months follow-up, LV ejection fraction, as well as other LV
echocardiographic parameters, signiﬁcantly improved in patients
with positive EMB ﬁndings of myocardial inﬂammation, but
remained unchanged in subjects with negative immunohisto-
chemistry. A signiﬁcant improvement of LV ejection fraction
was found regardless of viral genome presence or absence.
All patients improved in clinical status as assessed by NYHA
classiﬁcation.
These results may seem rather controversial with respect
to data cited above; however, they are not entirely surprising.
There is solid evidence in recently published literature that
simple ﬁnding of viral genome(s) in the myocardium, at least
the DNA of parvovirus B19, cannot be simply put into
causative pathogenic relationship with the development of
DCM. Kuethe et al. studied samples of left-atrium tissues
from 100 patients who underwent open-heart surgery
because of valve replacement of coronary artery bypass
grafting [25]. In 85% of these individuals, the genome of
parvovirus B19 was detected. In another study, Lotze et al.
found similar frequency (50% vs. 45%) of parvovirus B19
genomes in EMB samples taken from 24 patients with DCM
and in tissue of right atrial appendages of 10 control subjects
undergoing bypass surgery with normal LV ejection fraction
[26]. In agreement with the results of Krejčí et al., Kuethe et al.
demonstrated in another study similar improvement in LV
ejection fraction in patients acute DCM regardless the pre-
sence or absence of viral genome in baseline EMB [27].
Therefore, intensive research is aimed to improve diagnostics
of clinical relevance of the viral presence in the myocardium;
simply said: how to distinguish when the virus is responsible
for the development of LV dysfunction and DCM, respec-
tively, and it is still worth to ﬁght with him by speciﬁc
treatment approaches, and when the virus sitting in the
myocardium is just an “innocent bystander”. In this context,
main attention is currently paid to quantiﬁcation of viral load
and replication [28].
Furthermore, the patients followed in previously men-
tioned studies were diagnosed within the ﬁrst or at the
beginning of the second decade of this century and thus were
not treated with the whole pharmacological armamentarium
available at current era. In the study of Kindermann et al., 85%
of patients took ACE inhibitors or angiotensin receptor antago-
nist, but only 57% of were treated with betablockers and 38%
with aldosterone antagonists, respectively; similar numbers
may be found in the study of Kühl et al. [9,10]. On the other
hand, all patients in the study of Krejčí et al. were treated with
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mendations and the difference between evolutions of LV
ejection fraction of patients with positive and negative EMB
evidence for myocardial inﬂammation was noted. In almost
similarly conducted study, Zimermann et al. followed 82
patients with DCM for 7 months after EMB and found sig-
niﬁcant improvement in functional status and LV echocardio-
graphic parameters in both patients with and without
immunohistochemical signs of inﬂammation treated by stan-
dard heart failure medication; however, signiﬁcantly better
outcome concerning echocardiographic parameters and NYHA
classiﬁcation was observed in subjects with baseline EMB
positivity for myocardial inﬂammation [29]. Of note, almost
all patients in both groups were treated by ACE inhibitors/
angiotensin receptor blockers and betablockers. One may thus
hypothesize that EMB positivity of myocardial inﬂammation
might represent a good prognostic indicator for positive LV
response to modern heart failure medical therapy and higher
probability of at least partial LV reversal remodeling and
functional recovery. Of course, further studies investigating
this issue are needed. Nevertheless, it is clear that in con-
siderable number of patients with recent-onset DCM a sig-
niﬁcant improvement of initially severely depressed LV
ejection fraction will occur as was also documented in some
other recent studies [30,31]. Therefore, as already stated in
current European Society of Cardiology Guidelines for
the diagnosis and treatment of acute and chronic heart failure,
a primary preventive implantation of the implantable
cardioverter-deﬁbrillator in patients with newly diagnosed
DCM should be considered only after a sufﬁcient period of
optimal medical therapy (at least 3 months) after which LV
ejection fraction remains below 35% [32].
To conclude, there are many questions left unanswered
concerning the diagnostics, prognosis and treatment of ICM.
Some were already mentioned above: more precise deﬁnition of
clinical and prognostic relevance of persistent viral genome in
the myocardium as well as myocardial inﬂammation, accurate
identiﬁcation of the individuals with newly diagnosed DCM
whose LV systolic function will considerably improve or even
normalize with standard heart failure medication and those
who's LV will not be able to reverse remodeling. Together with
these issues, more work is needed to determine who and when
will beneﬁt from tailored antiviral, immunomodulatory or
immunosuppressive therapy. The fascinating story on better
understanding ICM goes on!
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